Aroa Biosurgery Ltd (ASX: ARX) Share Price and News

Mr Diddams is a resident of Australia and has over forty years of experience as a CFO, CEO, and director of both private and publicly listed companies. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in several diverse industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors.

Mr McCaw is a resident of New Zealand and is the Founding Partner of Movac, one of New Zealands Venture Capital funds. He led the original investment round into AROA in 2008, has worked closely with the Company and has served on the Board since then. He is also Chair of the New Zealand Government's Startup Advisors Council, established to help identify and address the opportunities and challenges facing high growth start-up businesses. Phil has over 20 years of experience investing into New Zealand technology companies and helping to guide their growth. He was an early investor in Trade Me, New Zealand's leading on-line trading community, which was sold to Fairfax in 2006.

Mr McLean is a resident of New Zealand. He has over 25 years of experience serving as chair, director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to AROA, current appointments include Chair of Prevar Limited and R J Hill Laboratories. He was Chair of the New Zealand Institute of Plant and Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as Deputy Chair. Jim was an executive and director of Genesis Research and Development Corporation during its early stages through to public listing.

Mr Pinion II is a resident of the US. He has over 30 years of global experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe, and the Americas. His expertise and leadership spans engineering, quality, manufacturing, and translational sciences. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical QC. He is also Chair of Risk committee.

Mr Ward is the founder of AROA and a resident of New Zealand. He has held senior corporate roles in life sciences and health care companies for more than 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development, and strategy having worked for several multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on several government and industry expert panels. Brian has been responsible for leading AROA's growth from start-up through to the present.

Dr Mohr is a New Zealand citizen and resident of the US. She has over 30 years of experience across fields, including engineering, healthcare, alternative energy, aerospace, and global entrepreneurship. Her expertise spans many areas related to AROA's next stage of growth, including medtech product research and development, FDA approvals, product commercialisation and surgery technology innovation. She has been President of the Intuitive Foundation since 2018. Prior to leading the Foundation, Catherine held senior roles at Intuitive Surgical, including Vice President of Strategy and Director of Medical Research. Intuitive Surgical is a pioneer in the robotic-assisted surgery field and developed the da Vinci surgical robotic system which is used in millions of surgical procedures across the globe every year. She is also a member of risk committee.

Ms Hutton brings over 25 years of leadership expertise in life sciences commercial strategy, operations, sales, marketing and data analytics. She is currently Vice President of Commercial Operations and Marketing-Asia, at Silicon Valley-based Intuitive Surgical, Inc., the global leader in minimally invasive care.Ms Hutton has held roles of responsibility at Intuitive, including Vice President of Corporate Accounts-US and Vice President of Marketing, Market Access & Custom Hospital Analytics . Ms Hutton is also a member of the compans Diversity Council. Ms Hutton has previously held commercial positions at global medical technology and pharmaceutical companies, including Boston Scientific and GlaxoSmithKline

-

-

-

-

-

-

-

-

-

-

-

-

-